Near-term strategies for biotech drug developers facing shifting healthcare dynamics
A dynamic convergence of economic, legislative, scientific, and technological influences is molding the future of the healthcare industry – with implications for biotech companies. Healthcare environments are becoming increasingly complex as drug developers increasingly make the transition to next-generation therapeutics, driving demand for clinical innovation. Against this backdrop, the industry continues to pioneer new approaches to engaging with patients, clinical trial teams, and healthcare providers. During a recent panel discussion, Goldman Sachs and Parexel shared perspectives on emerging trends and high-level developments to help biotechs plan their short- and near-term strategies.
Get more insights from our recent panel discussion with Goldman Sachs, entitled “Decoding Healthcare’s Future: A comprehensive analysis of investment, clinical research and regulatory dynamics.”
The views and opinions expressed by the authors are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs, or Parexel, for you to take any action.
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Playbook
Are you using real-world evidence?
Feb 1, 2023
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Playbook
Are you using real-world evidence?
Feb 1, 2023
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023